

Applicants:	Jessica Teeling, Sigrid Ruuls, Martin Glennie, Jan G. J. van de Winkel, Paul Parren, Jørgen Petersen, Ole Baadsgaard and Haichun Huang		
Application No.:	10/687,799	Group:	1644
Filed:	October 17, 2003	Examiner:	Ronald B. Schwadron
Confirmation No:	1801		
For:	Human Monoclonal Antibodies Against CD20		

REQUEST FOR CORRECTION OF ERRORS IN SEQUENCE LISTING PURSUANT TO 37  
C.F.R. § 1.825 AND TRANSMITTAL OF SECOND SUBSTITUTE SEQUENCE LISTING

Sir:

Specifically, SEQ ID NOs: 2, 4, 6, 8, 10 and 12 are being amended to delete their leader sequences because inclusion of the leader sequences was made in error, as supported by the Statement by Dr. Tom Vink. SEQ ID NOs: 13, 19 and 25 are also being amended to delete one extra amino acid from their respective N-termini because inclusion of the extra amino acid was made in error, as supported by the statement of Dr. Tom Vink. Attached herewith is a mark-up showing the changes being made to only those sequences that are being amended in the Second Substitute

Sequence Listing. Deletions are shown by strikethrough.


Pursuant to 37 C.F.R. § 1.825, Applicants hereby state that no new matter has been added to the Second Substitute Sequence Listing. The corrections are being made to correct obvious errors that would have been appreciated by the skilled person. This appreciation is discussed in the Statement of Dr. Vink. Dr. Vink stated that the variable heavy chain and light chain amino acid sequences set forth in SEQ ID NOs: 2, 4, 6, 8, 10 and 12 contain the leader sequences by obvious mistake and that nothing else was intended than to define the mature antibodies without these leader sequences. Further, Dr. Vink also stated that it is obvious that when applying the Kabat numbering rules to the V<sub>H</sub> CDR1 regions, the respective V<sub>H</sub> CDR1 regions should be "Asp Tyr Ala Met His" for SEQ ID NO:13, "Asp Tyr Ala Met His" for SEQ ID NO:19 and "Tyr His Ala Met His" for SEQ ID NO:25. When comparing the rules to the V<sub>H</sub> CDR1 sequences in the application, it appears that, by mistake, an extra amino acid has been added to these V<sub>H</sub> CDR1 sequences. For these reason, it is believed that correction of the errors in the Second Substitute Sequence Listing is for purposes of clarification which does not result in addition of new matter.

In accordance with procedures regarding electronically filed applications containing a sequence listing in text format, Applicants state that the sequences contained in the Second Substitute Sequence Listing do not go beyond the sequences disclosed in the specification of the application as it was originally filed on October 17, 2003. Additionally, it is understood that since the Second Substitute Sequence Listing is being submitted electronically, the requirement for submission of a computer readable form under 37 CFR 1.821(e) has been met.

Please insert the attached "Second Substitute Sequence Listing" into the application.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By 

Alice O. Carroll

Registration No. 33,542

Telephone: (978) 341-0036

Facsimile: (978) 341-0136

Concord, MA 01742-9133

Date: November 3, 2010